Veradermics priced a $256.3 million initial public offering to advance VDPHL‑01, an oral formulation of minoxidil designed to avoid cardiovascular risks of systemic dosing. The proceeds will support three ongoing pivotal trials; the company expects preliminary data from the first of three pivotal studies in H1 2026. The upsized IPO signals investor appetite for dermatology and aesthetic biotech stories tied to late‑stage efficacy readouts.